Insilico Medicine

Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI

Retrieved on: 
목요일, 12월 1, 2022
COVID-19, Doctor of Philosophy, University of Copenhagen, Peripheral nervous system, DNA repair, AI, University, Chemistry, DNA, Gene, Degenerative disease, Associate, Patient, Survival analysis, Ageing, Biomarker, Insilico Medicine, Disease, MD, PLK1, Human, Assistant, Cancer, Cell division, ALS, Hope, Chicago (franchise), Research, Immunity, Gene expression, Intelligence, Fibrosis, Publication, Nature Cell Biology, Medicine, Sarcoma, Survival, Amyotrophic lateral sclerosis, University of Copenhagen Faculty of Health and Medical Sciences, Biology, Longevity, Safety, Idiopathic pulmonary fibrosis, Algorithm, Medical device, Pharmaceutical industry, Vaccine, CEP135

The findings, supported by researchers from the University of Chicago, were published in the Nov. 26 edition of Nature Cell Death & Disease .

Key Points: 
  • The findings, supported by researchers from the University of Chicago, were published in the Nov. 26 edition of Nature Cell Death & Disease .
  • With the most significantly perturbed genes serving as biomarkers, researchers performed survival analysis across 33 cancer types and selected those that showed high confidence stratification among cancer patients.
  • Insilico Medicines AI-driven PandaOmics platform was used to perform a comprehensive differential gene expression analysis, survival stratification, and target discovery.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.

Insilico Medicine to Present at 41st Annual J.P. Morgan Healthcare Meeting

Retrieved on: 
화요일, 11월 29, 2022
COVID-19, Doctor of Philosophy, Pharma, Peripheral nervous system, AI, Chemistry, Sanofi, Partnership, Insilico Medicine, Cancer, Therapy, Immunity, Fibrosis, Intelligence, Medicine, Biology, Fosun Pharma, Idiopathic pulmonary fibrosis, Medical device

New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine will present at the 41st Annual J.P. Morgan Healthcare Meeting happening Jan. 9-12, 2023 at the Westin St. Francis Hotel in San Francisco.

Key Points: 
  • New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine will present at the 41st Annual J.P. Morgan Healthcare Meeting happening Jan. 9-12, 2023 at the Westin St. Francis Hotel in San Francisco.
  • Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.
  • Headquartered in Hong Kong, Insilico Medicine has additional offices in New York, Montreal, Shanghai, Suzhou, Taipei, and Abu Dhabi.

Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI

Retrieved on: 
수요일, 11월 23, 2022
Degenerative disease, Doctor of Philosophy, Pharma, Peripheral nervous system, AI, Chemistry, Bill, Insilico Medicine, World Health Organization, Birth, Infection, Cancer, In silico, Immunity, Intelligence, Fibrosis, Medicine, Bill & Melinda Gates Foundation, Woman, Pregnancy, Biology, Drug discovery, Pharmaceutical industry, Medical device

Petrina Kamya, PhD, Head of AI Platforms at Insilico Medicine, participated in the foundations Fall 2022 Non-hormonal Contraceptive Discovery Convening and Grand Challenges Annual Meeting Oct. 22-27 in Brussels.

Key Points: 
  • Petrina Kamya, PhD, Head of AI Platforms at Insilico Medicine, participated in the foundations Fall 2022 Non-hormonal Contraceptive Discovery Convening and Grand Challenges Annual Meeting Oct. 22-27 in Brussels.
  • Were thrilled to have the opportunity to use our AI drug discovery and design platform to help design new birth control options for women across the world which represents a major unmet need, says Dr. Kamya.
  • Using its Pharma.AI platform, Insilico will develop completely new small molecules to further interrogate and evaluate targets that could possibly lead to a contraceptive effect.
  • Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.

Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion

Retrieved on: 
화요일, 11월 8, 2022
GLOBE, Fibrosis, Immunity, Doctor of Philosophy, Intelligence, Insilico Medicine, Biomedical Research, Research, Biology, Drug discovery, China Research Group, Solution, Pharma, Drug development, Cancer, Sanofi, CEO, Therapy, Central nervous system, Medicine, Chemistry, CNS, Medical device

Abu Dhabi, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi.

Key Points: 
  • Abu Dhabi, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi.
  • We look forward to working with Insilico Medicine, a demonstrated leader in AI-powered drug discovery, said Changchun Xiao, Head of China Research at Sanofi.
  • Additional payments will be made if key research, development, and sales milestones are met, and could total up to $1.2 billion.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.

Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion

Retrieved on: 
화요일, 11월 8, 2022
GLOBE, Fibrosis, Immunity, Doctor of Philosophy, Insilico Medicine, Intelligence, Biomedical Research, Research, Biology, Drug discovery, China Research Group, Solution, Pharma, Drug development, Cancer, Sanofi, Chemistry, Therapy, CEO, Central nervous system, Medicine, CNS, Medical device

New York, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi.

Key Points: 
  • New York, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi.
  • We look forward to working with Insilico Medicine, a demonstrated leader in AI-powered drug discovery, said Changchun Xiao, Head of China Research at Sanofi.
  • Additional payments will be made if key research, development, and sales milestones are met, and could total up to $1.2 billion.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases.

Longenesis Partners with Dante Genomics to Offer Whole Genome Sequencing Solutions for Women’s Health in Europe

Retrieved on: 
화요일, 11월 1, 2022
DNA, CEO, Software as a service, Health, Genomics, Partnership, GLOBE, Research, Whole genome sequencing, Physician, WGS, Privacy, Human, AI, VP, Ethics, Insilico Medicine, Medicine, Company, Woman, Patient, Longevity, Precision medicine, Therapy, Antibiotics, Vaccine, Baltic

LAQUILA, Italy, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Biotechnology startup Longenesis has partnered with Dante Genomics , a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants.

Key Points: 
  • LAQUILA, Italy, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Biotechnology startup Longenesis has partnered with Dante Genomics , a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants.
  • This collaboration will encourage more people to pursue genomic solutions to help make personalised medicine more mainstream across Europe.
  • The Longenesis platform offers a digital, dynamic, secure engagement tool that empowers the public to explore and start using Dantes novel genomic solutions.
  • Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI.

AI and Biotech Pioneer Alex Zhavoronkov Commits His Life, Estate to Longevity for All

Retrieved on: 
화요일, 10월 25, 2022
Time, Therapy, Deep learning, Life, Telecommunication, Laboratory, MSU, University of Copenhagen Faculty of Health and Medical Sciences, Longevity, Intelligence, Biotechnology, Buck Institute for Research on Aging, Michigan State University College of Natural Science, Research, PNAS, Ageing, Johns Hopkins University, Artificial intelligence, University, Insilico Medicine, Biomarker, Drug discovery, Forbes, Doctor of Philosophy, Industry, CEO, Palgrave Macmillan, Ill, Climate change, GPU, Copenhagen, Regenerative medicine, Robotics, Biostasis, Hematology, Biophysics, In silico, Pharmaceutical industry, Nature, Science

DUBAI, United Arab Emirates, Oct. 25, 2022 /PRNewswire/ -- Today, the artificial intelligence, biotech and longevity pioneer Alex Zhavoronkov, PhD, has publicly called for the world's most successful founders, altruistic billionaires, and dedicated longevity pioneers to join him in his unorthodox and principled "Longevity Pledge."

Key Points: 
  • Alex Zhavoronkov, PhD, is the founder and Chief Longevity Officer of Deep Longevity, the founder and CEO of Insilico Medicine, and an adjunct professor at the esteemed Buck Institute for Research on Aging.
  • Today, Alex Zhavoronkov formally announced his personal " Longevity Pledge ."
  • "Making productive longevity, or the ability to live a longer, healthier life, is the most altruistic cause you can support," said Alex Zhavoronkov.
  • Learn more about Alex Zhavoronkov and the Longevity Pledge at www.LongevityPledge.org .

AI and Biotech Pioneer Alex Zhavoronkov Commits His Life, Estate to Longevity for All

Retrieved on: 
화요일, 10월 25, 2022
Time, Therapy, Deep learning, Life, Telecommunication, Laboratory, MSU, University of Copenhagen Faculty of Health and Medical Sciences, Longevity, Intelligence, Biotechnology, Buck Institute for Research on Aging, Michigan State University College of Natural Science, Research, PNAS, Ageing, Johns Hopkins University, Artificial intelligence, University, Insilico Medicine, Biomarker, Drug discovery, Forbes, Doctor of Philosophy, Industry, CEO, Palgrave Macmillan, Ill, Climate change, GPU, Copenhagen, Regenerative medicine, Robotics, Biostasis, Hematology, Biophysics, In silico, Pharmaceutical industry, Nature, Science

DUBAI, United Arab Emirates, Oct. 25, 2022 /PRNewswire/ -- Today, the artificial intelligence, biotech and longevity pioneer Alex Zhavoronkov, PhD, has publicly called for the world's most successful founders, altruistic billionaires, and dedicated longevity pioneers to join him in his unorthodox and principled "Longevity Pledge."

Key Points: 
  • Alex Zhavoronkov, PhD, is the founder and Chief Longevity Officer of Deep Longevity, the founder and CEO of Insilico Medicine, and an adjunct professor at the esteemed Buck Institute for Research on Aging.
  • Today, Alex Zhavoronkov formally announced his personal " Longevity Pledge ."
  • "Making productive longevity, or the ability to live a longer, healthier life, is the most altruistic cause you can support," said Alex Zhavoronkov.
  • Learn more about Alex Zhavoronkov and the Longevity Pledge at www.LongevityPledge.org .

Deepfake Technology in Drug Design

Retrieved on: 
목요일, 10월 20, 2022
Adoption, Time, Pharma, Stanford University School of Medicine, Stanford School, CB Insights, Disease, IPF, Pfizer, NVIDIA, Social impact, Nobel Prize, Immunity, Degenerative disease, Intelligence, Patient, Biology, Codex, Inflammation, Fosun Pharma, Technology, Cancer, Infection, Insilico Medicine, Company, Drug discovery, Doctor of Philosophy, Peripheral nervous system, AI, Q&A, CEO, Nobel Prize in Physiology or Medicine, GLOBE, Fibrosis, Robotics, Solution, In silico, Medical device, Pharmaceutical industry, Chemistry, Medicine

New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage artificial intelligence (AI)-driven drug discovery company, is utilizing the same deepfake technology used to create artwork and lifelike images of virtual human beings to design new molecules that have the potential to treat disease.

Key Points: 
  • New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage artificial intelligence (AI)-driven drug discovery company, is utilizing the same deepfake technology used to create artwork and lifelike images of virtual human beings to design new molecules that have the potential to treat disease.
  • Insilicos end-to-end AI platform, Pharma.AI, can discover new targets, design new drugs, and, now, predict the outcomes of clinical trials.
  • This technology can substantially improve the time and cost to bring new life-saving drugs to market.
  • Weve shown just how far this technology can go, with the first AI-discovered target and AI-designed drug in Phase 1 clinical trials.

Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region’s biotechnology capabilities

Retrieved on: 
수요일, 9월 14, 2022
Software, Peripheral nervous system, Saudi Arabia, Global, Roche, Memorandum of understanding, Fibrosis, Longevity, Company, MISA, GSK, Partnership, Immunity, Industry, Clinical trial, Intelligence, Cancer, CEO, Technology, Biology, AstraZeneca, Solution, Novartis, Doctor of Philosophy, Drug development, Robotics, Insilico Medicine, Microsoft, Research, Janssen, GLOBE, AI, Drug discovery, Medicine, Kingdom, Chemistry, Medical device

MISA and Insilico Medicine will work on shared initiatives that build on the capabilities of Insilicos end-to-end AI-powered drug discovery platform, PharmaAI.

Key Points: 
  • MISA and Insilico Medicine will work on shared initiatives that build on the capabilities of Insilicos end-to-end AI-powered drug discovery platform, PharmaAI.
  • Insilico will also work with Saudi companies on robotics-aided drug design and clinical trial design and best practices.
  • Insilico Medicine, a company which bridges pharma and tech, is the first AI-driven drug discovery company to sign such an agreement in the region.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.